Cascadian Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cascadian Therapeutics, Inc.
Plus deals involving Sanofi/SIRION, Merck KGAA/Day One, Beijing Tide/Graviton, Vaccinex/Surface Oncology, Athena/Tris, Biomunex/Onward, Cellectis/Cytovia
A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
Multiple COVID-19 vaccines, including from J&J, Pfizer and RDIF, are seen gaining approvals in India in 2021, following on from a raft of R&D, manufacturing and marketing tie-ups, as well as other developments, in the action-packed field last year.
- Large Molecule
- Other Names / Subsidiaries
- Alpine Biosciences
- Oncothyreon, Inc.
- Seattle Genetics, Inc.s